John P. Saharek
2015
In 2015, John P. Saharek earned a total compensation of $1M as Chief Commercial Officer at Imprimis Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $66,000 |
|---|---|
| Option Awards | $534,600 |
| Salary | $201,315 |
| Stock Awards | $221,100 |
| Other | $8,142 |
| Total | $1,031,157 |
Saharek received $534.6K in option awards, accounting for 52% of the total pay in 2015.
Saharek also received $66K in non-equity incentive plan, $201.3K in salary, $221.1K in stock awards and $8.1K in other compensation.
Rankings
In 2015, John P. Saharek's compensation ranked 7,803rd out of 13,638 executives tracked by ExecPay. In other words, Saharek earned more than 42.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,803 out of 13,638 | 43rd |
Division Manufacturing | 2,957 out of 5,190 | 43rd |
Major group Chemicals And Allied Products | 1,068 out of 1,854 | 42nd |
Industry group Drugs | 861 out of 1,528 | 44th |
Industry Pharmaceutical Preparations | 679 out of 1,182 | 43rd |
Source: SEC filing on April 27, 2017.
Saharek's colleagues
We found two more compensation records of executives who worked with John P. Saharek at Imprimis Pharmaceuticals in 2015.
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019